Activation of ZBP1/RIPK3/MLKL-Dependent Necroptosis by Pseudorabies Virus Restricts Viral Infection in BV2 Microglia Cells

伪狂犬病毒激活ZBP1/RIPK3/MLKL依赖性坏死性凋亡可限制BV2小胶质细胞中的病毒感染

阅读:2
作者:Yiyu Liu,Haolin Li,Yu Dai,Jingyi Niu,Linhan Jiang,Jia Tang,Rendong Fang,Chao Ye

Abstract

Pseudorabies (PR) virus (PRV), also known as suid herpesvirus 1, is an alphaherpesvirus that causes huge economic losses in the global swine industry. Necroptosis, a caspase-independent programmed cell death, has been demonstrated to play an important role in regulating viral infections. Here, we showed that PRV infection triggered receptor-interacting protein (RIP) kinase (RIPK) 3/mixed lineage kinasedomain-like (MLKL)-dependent necroptosis in BV2 microglial cells. Mechanistically, PRV infection induced the formation of Z-DNA and upregulated the expression of Z-nucleic acid-binding protein 1 (ZBP1), leading to ZBP1-RIPK3 interaction that triggered the RIPK3/MLKL-dependent necroptosis pathway. Additionally, both RNA interference and protein overexpression experiments demonstrated that RIPK3 and MLKL independently restricted PRV infection in BV2 microglial cells. The underlying mechanism lay in the fact that RIPK3 and MLKL can independently enhance the interferon (IFN)-β signaling pathway. Similarly, pharmacological inhibition of RIPK3 and MLKL using GW806742X and UH15-38 promoted PRV infection in BV2 microglial cells; however, this treatment did not affect IFN-β pathway activation. Taken together, our study elucidated the molecular mechanism of ZBP1/RIPK3/MLKL-dependent necroptosis activation during PRV infection and revealed that necroptosis signaling exerted anti-PRV effects in BV2 microglia cells. These findings provided novel insights into the antiviral defense mechanisms of microglia in the central nervous system (CNS) and suggested that targeting necroptosis signaling may offer a therapeutic strategy for controlling PRV infection.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。